Clinical trialNCT04260022RecruitingPhase 1Interventional

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

SponsorAscentage Pharma Group Inc.Enrollment242B Cell Precursor Type Acute LeukemiaChronic Myeloid LeukemiaLeukemia, Myeloid, ChronicMyeloid LeukemiaPhiladelphia Positive Acute Lymphoblastic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Dennis Kim, MD
Recruiting

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Omer Jamy, MD
Recruiting
City of Hope
Duarte, California, United States
Paul Koller, MD
Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Anthony Hunter, MD
Recruiting
Augusta Cancer Center
Augusta, Georgia, United States
Jorge Cortes, MD
Recruiting
University of Maryland
Baltimore, Maryland, United States
Maria Baer, MD
Recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Sudipto Mukherjee, MD
Recruiting
University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Elias Jabbour, MD
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Vivian Oehler, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ascentage Pharma HQP1351 bioavailable inhibitorBlinatumomab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Jan 2020
Primary completion: 27 Dec 2029
Completion: 31 Mar 2030
Last update posted: 5 Nov 2025
Registered enrollment: 242
Registry id: NCT04260022

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.